Abstract
INTRODUCTION: The present study evaluated the prognostic significance of panimmune-inflammation value (PIV) and PILE (a composite score of PIV, lactate dehydrogenase [LDH], and Eastern Cooperative Oncology Group Performance Status [ECOG PS]) in patients with non-metastatic luminal A breast cancer. METHODS: Non-metastatic stage (I-III) luminal A breast cancer patients who were admitted to Cumhuriyet University Oncology Center were retrospectively examined. The PIV score was calculated using the neutrophil, platelet, monocyte, and lymphocyte counts at the time of diagnosis. The PIV, LDH, and ECOG PS parameters were used for the PILE score. RESULTS: A total of 293 patients were included. The median PIV was 254.89; 239 (82%) patients had low PILE score; and 54 (18%) patients had high PILE score. Patients with low PIV and low PILE scores had significantly better OS and disease-free survival (DFS) (PIV; p = 0.033 for OS and p = 0.024 for DFS and PILE; p = 0.001 for OS and p = 0.005 for DFS). The PIV and PILE scores were found to be significant prognostic factors associated with OS and DFS. The PIV score was found to be an independent prognostic factor for OS and DFS (OS: score 0 vs. 1; HR: 1.89, 95% CI: 1.06-3.35; p = 0.029; and DFS: score 0 vs. 1; HR: 1.75, 95% CI: 1.01-3.01; p = 0.044). The PILE score was not an independent prognostic factor associated with OS or DFS. CONCLUSION: Survival was better in those with lower PIV and PILE scores. The PIV score was an independent prognostic factor for survival in these patients.